SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|
Assets | ||||||||
Assets Current | ||||||||
Cash And Cash Equivalents At Carrying Value | 223 | 239 | 96 | |||||
Debt Securities Held To Maturity Amortized Cost Af… | 11 | 12 | 11 | |||||
Other Receivables Net Current | 1 | 1 | 0 | |||||
Prepaid Expense And Other Assets Current | 2 | 2 | 1 | |||||
Assets Current | 236 | 253 | 109 | |||||
Other Assets Noncurrent | 1 | 1 | 0 | |||||
Property Plant And Equipment Net | 5 | 3 | 2 | |||||
Operating Lease Right Of Use Asset | 1 | 1 | 2 | |||||
Assets | 243 | 258 | 116 | |||||
Liabilities And Stockhold… | ||||||||
Liabilities Current | ||||||||
Accounts Payable Current | 4 | 4 | 3 | |||||
Employee Related Liabilities Current | 2 | 1 | 2 | |||||
Other Liabilities Current | 4 | 2 | 4 | |||||
Liabilities Current | 9 | 7 | 9 | |||||
Operating Lease Liability Current | - | 0 | 0 | |||||
Shares Subject To Mandatory Redemption Settlement … | - | - | 0 | |||||
Operating Lease Liability Noncurrent | 2 | 2 | 2 | |||||
Liabilities | 11 | 8 | 10 | |||||
Temporary Equity Carrying Amount Attributable To P… | 0 | 0 | 205 | |||||
Equity | ||||||||
Preferred Stock Value | 0 | 0 | - | |||||
Common Stock Value | 0 | 0 | 0 | |||||
Additional Paid In Capital | 371 | 369 | 6 | |||||
Retained Earnings Accumulated Deficit | -138 | -119 | -105 | |||||
Stockholders Equity | 232 | 250 | -99 | |||||
Liabilities And Stockholders Equity | 243 | 258 | 116 | |||||
Temporary Equity Par Or Stated Value Per Share | 0 | 0 | 0 | |||||
Temporary Equity Shares Authorized | 0 | 0 | 117 | |||||
Temporary Equity Shares Issued | 0 | 0 | 20 | |||||
Temporary Equity Shares Outstanding | 0 | 0 | 20 | |||||
Temporary Equity Liquidation Preference | 0 | 0 | 201 | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | - | |||||
Preferred Stock Shares Authorized | 200 | 200 | - | |||||
Preferred Stock Shares Issued | 0 | 0 | - | |||||
Preferred Stock Shares Outstanding | 0 | 0 | - | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 1,000 | 1,000 | 154 | |||||
Common Stock Shares Issued | 33 | 33 | 2 | |||||
Shares Outstanding | 33 | 33 | 2 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|
| 2026 | -22.62% | -21.10% | -7.17% | - | - | - | - | - | - |
| 2025 | - | - | - | - | - | - | -1.03% | -7.90% | -26.83% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | |||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
SpyGlass Pharma, Inc. (SGP) — SEC Financial Statements & Analysis
SpyGlass Pharma, Inc. (SGP) is a surgical & medical instruments & apparatus company, incorporated in DE. SpyGlass Pharma, Inc. trades on Nasdaq as: SGP. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), SpyGlass Pharma, Inc. reported a Debt-to-Equity ratio of 0.05x, a Price-to-Book (P/B) ratio of 3.20x (TTM), at a market cap of $744.36M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.05x
- P/B TTM
- 3.20x
- Market Cap
- $744.36M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is SpyGlass Pharma, Inc. in?
SpyGlass Pharma, Inc. (SGP) operates in the Surgical & Medical Instruments & Apparatus industry.
What is SGP's market cap?
SpyGlass Pharma, Inc. (SGP) has a market capitalization of $744.36M as of 2026-06-30.
What exchange does SGP trade on?
SpyGlass Pharma, Inc. (SGP) trades on the Nasdaq.
Where is SpyGlass Pharma, Inc. incorporated?
SpyGlass Pharma, Inc. is incorporated in DE.